U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H27N5O4
Molecular Weight 389.4495
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALFUZOSIN

SMILES

CN(CCCN=C(C1CCCO1)O)c2nc3cc(c(cc3c(=N)[nH]2)OC)OC

InChI

InChIKey=WNMJYKCGWZFFKR-UHFFFAOYSA-N
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)

HIDE SMILES / InChI

Molecular Formula C19H27N5O4
Molecular Weight 389.4495
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl extended-release tablets) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

CNS Activity

Curator's Comment:: Alfuzosin does not penetrate the blood–brain barrier well

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
UROXATRAL

Approved Use

UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. (1) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. (1.1) UROXATRAL is not indicated for use in the pediatric population. (1.1, 8.4, 12.3) 1.1 Important Limitations of Use UROXATRAL is not indicated for the treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population.

Launch Date

1.05537602E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.6 ng/mL
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALFUZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
194 ng × h/mL
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALFUZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALFUZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
14%
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALFUZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
40 mg 1 times / day single, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
healthy, mean age 27 years
n = 45
Health Status: healthy
Age Group: mean age 27 years
Sex: M
Population Size: 45
Sources:
Other AEs: Dizziness, Headache...
Other AEs:
Dizziness (8.9%)
Headache (6.7%)
Malaise (2%)
Sources:
4.4 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 4.4 mg, 2 times / day
Route: oral
Route: multiple
Dose: 4.4 mg, 2 times / day
Sources:
unhealthy, mean age 62.6 years
n = 93
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 62.6 years
Sex: M
Population Size: 93
Sources:
Disc. AE: Abdominal pain, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (grade 1-2, 1.1%)
Diarrhoea (grade 1-2, 1.1%)
Dizziness (grade 1-2, 3.2%)
Headache (grade 1-2, 1.1%)
Ventricular fibrillation (grade 1-2, 1.1%)
Sources:
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Disc. AE: Vertigo, Syncope...
AEs leading to
discontinuation/dose reduction:
Vertigo (1.35%)
Syncope (0.55%)
Postural hypotension (0.42%)
Headache (0.39%)
Nausea (0.46%)
Abdominal pain (0.35%)
Diarrhoea (0.16%)
CNS disorder (NOS) (0.14%)
Asthenia (0.19%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Malaise 2%
40 mg 1 times / day single, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
healthy, mean age 27 years
n = 45
Health Status: healthy
Age Group: mean age 27 years
Sex: M
Population Size: 45
Sources:
Headache 6.7%
40 mg 1 times / day single, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
healthy, mean age 27 years
n = 45
Health Status: healthy
Age Group: mean age 27 years
Sex: M
Population Size: 45
Sources:
Dizziness 8.9%
40 mg 1 times / day single, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
healthy, mean age 27 years
n = 45
Health Status: healthy
Age Group: mean age 27 years
Sex: M
Population Size: 45
Sources:
Abdominal pain grade 1-2, 1.1%
Disc. AE
4.4 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 4.4 mg, 2 times / day
Route: oral
Route: multiple
Dose: 4.4 mg, 2 times / day
Sources:
unhealthy, mean age 62.6 years
n = 93
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 62.6 years
Sex: M
Population Size: 93
Sources:
Diarrhoea grade 1-2, 1.1%
Disc. AE
4.4 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 4.4 mg, 2 times / day
Route: oral
Route: multiple
Dose: 4.4 mg, 2 times / day
Sources:
unhealthy, mean age 62.6 years
n = 93
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 62.6 years
Sex: M
Population Size: 93
Sources:
Headache grade 1-2, 1.1%
Disc. AE
4.4 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 4.4 mg, 2 times / day
Route: oral
Route: multiple
Dose: 4.4 mg, 2 times / day
Sources:
unhealthy, mean age 62.6 years
n = 93
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 62.6 years
Sex: M
Population Size: 93
Sources:
Ventricular fibrillation grade 1-2, 1.1%
Disc. AE
4.4 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 4.4 mg, 2 times / day
Route: oral
Route: multiple
Dose: 4.4 mg, 2 times / day
Sources:
unhealthy, mean age 62.6 years
n = 93
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 62.6 years
Sex: M
Population Size: 93
Sources:
Dizziness grade 1-2, 3.2%
Disc. AE
4.4 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 4.4 mg, 2 times / day
Route: oral
Route: multiple
Dose: 4.4 mg, 2 times / day
Sources:
unhealthy, mean age 62.6 years
n = 93
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 62.6 years
Sex: M
Population Size: 93
Sources:
CNS disorder (NOS) 0.14%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Diarrhoea 0.16%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Asthenia 0.19%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Abdominal pain 0.35%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Headache 0.39%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Postural hypotension 0.42%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Nausea 0.46%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Syncope 0.55%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Vertigo 1.35%
Disc. AE
2.5 mg 3 times / day multiple, oral
Recommended
Dose: 2.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 3 times / day
Sources:
unhealthy, mean age 66.9 years
n = 13389
Health Status: unhealthy
Condition: benign prostatic hypertrophy
Age Group: mean age 66.9 years
Sex: M
Population Size: 13389
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: administration with ketoconazole increased alfuzosin Cmax and AUClast by, 2.3-fold and 3.2 fold, respectively; administration with diltiazem increased Cmax and AUC0-24 of alfuzosin 1.5-fold and 1.3-fold, respectively;
Page: 34.0
minor
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
2001
Initial choices and final outcomes in lower urinary tract symptoms.
2001
Long-term aspects of medical treatment of BPH.
2001
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
2001
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
2001 Jan
[Dalphaz-retard treatment of urination disorders in men and women].
2001 Jul-Aug
[Long-term therapy of benign prostatic hyperplasia. Our experience].
2001 Mar
Do alpha-blockers prevent the occurrence of acute urinary retention?
2001 Mar
Does acute urinary retention respond to alpha-blockers alone?
2001 Mar
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
2001 Mar
Worldwide experience with alfuzosin and tamsulosin.
2001 Oct
Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
2002
Alfuzosin: a clinically uroselective alpha1-blocker.
2002 Apr
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
2002 Apr
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.
2002 Dec 12
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
2002 Jan
[Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
2002 Jan-Feb
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
2002 Jul
Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder.
2002 Nov
[Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results].
2002 Sep
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
2003 Aug
Use of alpha-blockers and the risk of hip/femur fractures.
2003 Dec
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.
2003 Jul
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
2003 Jun
Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.
2003 May 25
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
2003 Nov
Alfuzosin for the management of benign prostate hyperplasia.
2003 Nov
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
2003 Sep
[Pharmacologic treatment of benign prostatic hyperplasia].
2003 Sep 14
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
2004
Priapism as a possible acute side effect of radical radiotherapy for prostate cancer.
2004 Apr
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
2004 Apr
Ejaculatory dysfunction and alpha-adrenoceptor antagonists.
2004 Aug
Real life practice in the management of benign prostatic hyperplasia.
2004 Jan
Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
2004 Jan 5
[Can selective alpha-blockers help the spontaneous passage of the stones located in the uretero-bladder junction?].
2004 Jan-Mar
[A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders].
2004 Jul
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
2004 Jun
Patients with bladder outlet obstruction who refuse treatment show no clinical and urodynamic change after long-term follow-up.
2004 Mar
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
2004 Mar
New drugs of 2003.
2004 Mar-Apr
Prostate size influences the outcome after presenting with acute urinary retention.
2004 Sep
Alfuzosin-induced acute hepatitis in a patient with chronic liver disease.
2004 Sep
Clinical assessment of drug-induced QT prolongation in association with heart rate changes.
2005 Apr
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
2005 Aug
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
2005 Aug
A pharmacoepidemiological approach to investigating inappropriate physician prescribing in a managed care setting in Israel.
2005 Feb
[The role of alpha1-adrenoblocker alfuzosine in diagnostic-therapeutic algorithm of hyperactive urinary bladder management in women and selection of patients for treatment with M-cholinergic antagonists].
2005 Jan-Feb
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
2005 Jul
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
2005 May
Patents

Sample Use Guides

Usual Adult Dose for Benign Prostatic Hyperplasia Extended-release tablet: 10 mg orally once a day immediately after the same meal each day
Route of Administration: Oral
In organ baths, isolated prostatic strips and isolated bladder strips were incubated with vehicle, tadalafil (10⁻⁶ M and 10⁻⁵ M), alfuzosin (3×10⁻⁸ M or 10⁻⁶ M and 10⁻⁵ M) or a combination. Concentration-response curves (CRCs) to norepinephrine were generated on prostatic strips and detrusor strips precontracted with carbachol. Strips were also submitted to electrical field stimulation (EFS). When alfuzosin and tadalafil were combined, the maximal relaxation to norepinephrine on carbachol-precontracted detrusor strips was significantly increased compared with tadalafil alone, and EFS-induced detrusor contractions were better inhibited compared with each compound alone. Tadalafil significantly inhibited norepinephrine-induced prostatic strip contractions by reducing the maximal effect, whereas alfuzosin shifted the CRC of norepinephrine to the right. Combining both tadalafil and alfuzosin resulted in a greater relaxant effect.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:51:53 UTC 2021
Edited
by admin
on Fri Jun 25 21:51:53 UTC 2021
Record UNII
90347YTW5F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALFUZOSIN
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
ALFUZOSIN [VANDF]
Common Name English
XATRAL
Brand Name English
ALFUZOSIN [HSDB]
Common Name English
2-FURANCARBOXAMIDE, (+/-)-N-(3-((4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)METHYLAMINO)PROPYL)TETRAHYDRO-
Systematic Name English
ALFUZOSIN [INN]
Common Name English
ALFUZOSIN [MI]
Common Name English
ALFUZOSIN [WHO-DD]
Common Name English
(+/-)-N-(3-((4-AMINO-6,7-DIMETHOXYQUINAZOLIN-2-YL)(METHYL)AMINO)PROPYL)TETRAHYDROFURAN-2-CARBOXAMIDE
Systematic Name English
NSC-760065
Code English
Classification Tree Code System Code
WHO-ATC G04CA51
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
WHO-VATC QG04CA51
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
WHO-VATC QG04CA01
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
LIVERTOX 24
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
NDF-RT N0000175553
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
NDF-RT N0000000099
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
NCI_THESAURUS C29713
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
WHO-ATC G04CA01
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
Code System Code Type Description
DRUG BANK
DB00346
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
RXCUI
17300
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY RxNorm
INN
5357
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
FDA UNII
90347YTW5F
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
EVMPD
SUB05319MIG
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
MERCK INDEX
M1501
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
ALFUZOSIN
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
PUBCHEM
2092
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
IUPHAR
7109
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
CAS
81403-80-7
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
EPA CompTox
81403-80-7
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
HSDB
7290
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
DRUG CENTRAL
115
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
NCI_THESAURUS
C61627
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL709
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
MESH
C047638
Created by admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
TARGET -> AGONIST
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
in vitro
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
FECAL
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
FECAL
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
FECAL
METABOLITE INACTIVE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC